

METEOROID study features

ClinicalTrials.gov ID NCT05271409



This clinical trial is split into two parts:


In **Part 1 (double-blind period)** everyone who joins this clinical trial will be split into two groups randomly and given either:

- **Satralizumab**

OR

- **Placebo.** Placebo is a medicine with no active ingredients, which is used to show that the doctor or the patient did not sway the results of the clinical trial.

Part 2 (open-label period). In Part 2 of the clinical trial, all participants will be given satralizumab for up to two years.



The trial started in 2022
and is expected to read out
in 2026